ArticleAntimicrobial agents and chemotherapy2025

Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective.

Thomas J Walsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.